Teleflex Reports Study Using Its Arrow® EZ-IO® Intraosseous Vascular Access System Shows Advantages for Medical Emergencies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. DPZ
7. NVDA
8. PRIM
9. META
10. SPY

Go back to Teleflex Reports Study Using Its Arrow® EZ-IO® Intraosseous Vascular Access System Shows Advantages for Medical Emergencies

Brean Capital Raises Price Target on Teleflex (TFX) to $145 Following 2Q Results

July 31, 2015 7:24 AM EDT

Brean Capital reiterated a Buy rating on Teleflex (NYSE: TFX), and raised the price target to $145.00 (from $135.00), following 2Q results. Teleflex reported 2Q15 adjusted EPS of $1.42, in line with consensus. Revenue was in line with expectations at $452.1 million, versus consensus estimate of $453 million.

Analyst Jason Wittes commented, "Teleflex reported 2Q15 adjusted EPS of $1.42, in line with consensus of $1.42 and $0.02 above our $1.40 estimate,... More